Mitral Valve, cardiovascular ultrasound, GE E95, cardiac ultrasound, comparison of ultrasound systems
Fujifilm, sonosite, iViz, POC ultrasound
cardiovascular ultrasound, GE E95
anatomical imaging, philips Epiq
lumify, app based ultrasound, Philips point of care ultrasound

(Read a 2018 update on cardiac ultrasound technologies "Recent Advances in Echocardiography Technology")

There were some big innovation trends in cardiac ultrasound in 2015. These included the launch of the first premium all touchscreen ultrasound system; the introduction of artificial intelligence to speed, simplify and make cardiac echo more reproducible; and a big advancement in image quality, approaching that of computed tomography (CT) scans.   

Researchers funded by the National Institute of Biomedical Imaging and Bioengineering (NIBIB) used ultrasound-activated microbubbles to improve preservation of heart muscle and function in a pig heart attack model. Based on this success, the method is now in phase I human clinical trials.

Royal Philips announced U.S. Food and Drug Administration (FDA) 510(k) clearance for the Expression MR400, a new technology that monitors patients undergoing magnetic resonance imaging (MRI).

February 10, 2016 — Fred Hoiberg, head coach of the National Basketball Assocation’s (NBA) Chicago Bulls, is launching a new patient education campaign featuring a video recounting his experience as a heart valve patient. The video premiered January 14 on www.HeartValveSurgery.com.


After five years of almost constant lobbying efforts and numerous attempts by the U.S. House to push through a repeal of the medical device tax, legislation passed in December suspends the tax for the next two years. President Barack Obama signed a $1.8 billion taxation and spending bill Dec. 18, the Consolidated Appropriations Act of 2016, ending the threat of a looming government shutdown. The bill also contained a variety of tax credits, including the two-year moratorium on the device tax.

CeloNova BioSciences Inc. announced this week that the first patient has been enrolled in its COBRA REDUCE trial. The COBRA REDUCE trial recently received conditional U.S. Food and Drug Administration (FDA) approval and will study the Cobra PzF nanocoated coronary stent (NCS) system in patients at high risk of bleeding.

February 10, 2016 — HeartWare International Inc. and Valtech Cardio Ltd. announced the termination of HeartWare's proposed acquisition of Valtech on January 28.

In a finding that could lead to new drugs to treat heart failure, researchers have uncovered the molecular mechanism that regulates how the heart pumps blood.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now